anhydrous enol-oxaloacetate (AEO) / MetVital - LARVOL DELTA

Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Jonsson Comprehensive Cancer Center | Trial completion date: Nov 2025 ➔ Nov 2026 | Trial primary completion date: Nov 2024 ➔ Nov 2025

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor

Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Jonsson Comprehensive Cancer Center | Trial completion date: Nov 2024 ➔ Nov 2025 | Trial primary completion date: Nov 2023 ➔ Nov 2024

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor

Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Jonsson Comprehensive Cancer Center | Trial completion date: Nov 2023 ➔ Nov 2024 | Trial primary completion date: Nov 2022 ➔ Nov 2023

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor

Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors (clinicaltrials.gov) - P2; N=24; Recruiting; Sponsor: Jonsson Comprehensive Cancer Center; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor

Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors (clinicaltrials.gov) - P2; N=24; Not yet recruiting; Sponsor: Jonsson Comprehensive Cancer Center; Trial completion date: Nov 2022 ➔ Nov 2023; Initiation date: Nov 2020 ➔ Feb 2021; Trial primary completion date: Nov 2021 ➔ Nov 2022

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor

MetVital, Inc. Announces FDA Fast Track Designation of Anhydrous Enol-Oxaloacetate (AEO) for the Treatment of Patients with Newly Diagnosed Glioblastoma Multiforme (PRNewswire) - "MetVital, Inc.,...announces that the U.S. Food and Drug Administration (FDA) has notified MetVital that its lead drug candidate, 'Anhydrous Enol-Oxaloacetate' (AEO) received Fast Track Designation for the treatment of patients with newly diagnosed glioblastoma multiforme (GBM). AEO, a patented molecule, is MetVital's lead clinical development candidate for treatment of glioblastoma multiforme, a malicious type of brain cancer."

Fast track designation • Glioblastoma • Oncology